| Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment P Cochat, SA Hulton, C Acquaviva, CJ Danpure, M Daudon, M De Marchi, ... Nephrology Dialysis Transplantation 27 (5), 1729-1736, 2012 | 367 | 2012 |
| Primary hyperoxaluria type 1: still challenging! P Cochat, A Liutkus, S Fargue, O Basmaison, B Ranchin, MO Rolland Pediatric nephrology 21, 1075-1081, 2006 | 192 | 2006 |
| Genotype–phenotype correlation in primary hyperoxaluria type 1: the p. Gly170Arg AGXT mutation is associated with a better outcome J Harambat, S Fargue, C Acquaviva, MF Gagnadoux, F Janssen, ... Kidney international 77 (5), 443-449, 2010 | 172 | 2010 |
| Disease recurrence in paediatric renal transplantation P Cochat, S Fargue, G Mestrallet, T Jungraithmayr, P Koch-Nogueira, ... Pediatric nephrology 24, 2097-2108, 2009 | 167 | 2009 |
| Primary hyperoxaluria J Harambat, S Fargue, J Bacchetta, C Acquaviva, P Cochat International journal of nephrology 2011, 2011 | 144 | 2011 |
| Multiple mechanisms of action of pyridoxine in primary hyperoxaluria type 1 S Fargue, G Rumsby, CJ Danpure Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1832 (10 …, 2013 | 116 | 2013 |
| Survey of first-year medical students to assess their knowledge and attitudes toward organ transplantation and donation D Mekahli, A Liutkus, S Fargue, B Ranchin, P Cochat Transplantation proceedings 41 (2), 634-638, 2009 | 103 | 2009 |
| Four of the most common mutations in primary hyperoxaluria type 1 unmask the cryptic mitochondrial targeting sequence of alanine: glyoxylate aminotransferase encoded by the … S Fargue, J Lewin, G Rumsby, CJ Danpure Journal of Biological Chemistry 288 (4), 2475-2484, 2013 | 98 | 2013 |
| Screening for NPHS2 mutations may help predict FSGS recurrence after transplantation TC Jungraithmayr, K Hofer, P Cochat, G Chernin, G Cortina, S Fargue, ... Journal of the American Society of Nephrology 22 (3), 579-585, 2011 | 98 | 2011 |
| Primary hyperoxaluria type 1: strategy for organ transplantation P Cochat, S Fargue, J Harambat Current Opinion in Organ Transplantation 15 (5), 590-593, 2010 | 84 | 2010 |
| Pharmacologic rescue of an enzyme-trafficking defect in primary hyperoxaluria 1 N Miyata, J Steffen, ME Johnson, S Fargue, CJ Danpure, CM Koehler Proceedings of the National Academy of Sciences 111 (40), 14406-14411, 2014 | 78 | 2014 |
| Effect of conservative treatment on the renal outcome of children with primary hyperoxaluria type 1 S Fargue, J Harambat, MF Gagnadoux, M Tsimaratos, F Janssen, ... Kidney international 76 (7), 767-773, 2009 | 70 | 2009 |
| End points for clinical trials in primary hyperoxaluria DS Milliner, TL McGregor, A Thompson, B Dehmel, J Knight, R Rosskamp, ... Clinical Journal of the American Society of Nephrology 15 (7), 1056-1065, 2020 | 66 | 2020 |
| Hydroxyproline metabolism and oxalate synthesis in primary hyperoxaluria S Fargue, DS Milliner, J Knight, JB Olson, WT Lowther, RP Holmes Journal of the American Society of Nephrology 29 (6), 1615-1623, 2018 | 63 | 2018 |
| Pyridoxamine and pyridoxal are more effective than pyridoxine in rescuing folding-defective variants of human alanine: glyoxylate aminotransferase causing primary hyperoxaluria … E Oppici, S Fargue, ES Reid, PB Mills, PT Clayton, CJ Danpure, B Cellini Human Molecular Genetics 24 (19), 5500-5511, 2015 | 58 | 2015 |
| Tacrolimus nephrotoxicity: beware of the association of diarrhea, drug interaction and pharmacogenetics S Leroy, A Isapof, S Fargue, M Fakhoury, A Bensman, G Deschênes, ... Pediatric Nephrology 25, 965-969, 2010 | 51 | 2010 |
| Contribution of dietary oxalate and oxalate precursors to urinary oxalate excretion JJ Crivelli, T Mitchell, J Knight, KD Wood, DG Assimos, RP Holmes, ... Nutrients 13 (1), 62, 2020 | 48 | 2020 |
| Reduction in urinary oxalate excretion in mouse models of primary hyperoxaluria by RNA interference inhibition of liver lactate dehydrogenase activity KD Wood, RP Holmes, D Erbe, A Liebow, S Fargue, J Knight Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1865 (9 …, 2019 | 42 | 2019 |
| Metabolism of 13C5-hydroxyproline in mouse models of primary hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline … X Li, J Knight, S Fargue, B Buchalski, Z Guan, EW Inscho, A Liebow, ... Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1862 (2), 233-239, 2016 | 40 | 2016 |
| Bone metabolism in oxalosis: a single-center study using new imaging techniques and biomarkers J Bacchetta, S Fargue, S Boutroy, O Basmaison, N Vilayphiou, I Plotton, ... Pediatric Nephrology 25, 1081-1089, 2010 | 33 | 2010 |
Pierre CochatProfesseur des Universités - Praticien HospitalierVerified email at chu-lyon.fr
